Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide
暂无分享,去创建一个
E. Lipp | H. Friedman | A. Desjardins | J. Herndon | M. Affronti | K. Peters | F. McSherry | S. Woodring | P. Healy | D. Randazzo | Mallika P. Patel | Elizabeth S. Miller